News | August 09, 2023

Boston Scientific Receives FDA Approval for the POLARx Cryoablation System

First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems 

First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) approval for the POLARx Cryoablation System. The new system, which is indicated for the treatment of patients with paroxysmal atrial fibrillation (AF), features the POLARx FIT Cryoablation Balloon Catheter, a device with the unique capability of enabling two balloon sizes – 28 and 31mm – in one catheter. 

Cryoablation is a minimally invasive procedure for treating AF during which a balloon catheter delivers cryotherapy to the pulmonary vein, freezing problematic tissue and creating scarring that blocks irregular electrical signals. The system addresses known limitations by reimagining existing cryoablation offerings, allowing physicians to adjust and expand the new POLARx FIT catheter to fit a patient's individual anatomy during an ablation procedure, which can help mitigate time-consuming and disruptive device changeouts. The device also allows physicians to treat a wider range of pulmonary vein anatomies and create lesions in optimal positions to better deliver therapy to areas of the heart where disruptive signals that cause AF originate. 

"The new POLARx Cryoablation System, and the expandable cryoballoon catheter specifically, is an exciting development for the effective treatment of AF as it allows physicians to better tailor care for individual patients without sacrificing safety or efficiency," said Wilber Su, MD, FHRS, FACC, Director of Electrophysiology, Banner University. "As we saw in clinical evaluation, the combination of maneuverability and variable balloon sizes makes this system particularly useful in addressing longstanding challenges with varying cardiac anatomies and brings to the table occlusion capabilities physicians aren't used to seeing with traditional systems." 

Data from the FROZEN-AF IDE clinical trial – a global, prospective, non-randomized, single-arm study presented at Heart Rhythm 2023 – demonstrated the safety and effectiveness of the POLARx Cryoablation System for the treatment of 385 patients with paroxysmal AF. The primary event-free rate, or freedom from procedure- or device-related events, was 96.0% at 12 months, with no reports of moderate or severe pulmonary vein stenosis, persistent phrenic nerve palsy or esophageal fistulas. At 12 months, the rate of freedom from documented atrial arrhythmias was 79.9%. 

"The U.S. approval of the POLARx Cryoablation System, which has been used in more than 25,000 patients worldwide to date, marks an exciting advancement for the treatment of AF and a new era of cryoablation capabilities," said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific. "By prioritizing procedural flexibility and individualized care, this offering transforms a key therapy in the electrophysiology space, addresses the unmet needs of physicians and affirms our commitment to making meaningful innovations to established technologies." 

The POLARx Cryoablation System received CE Mark in February of 2020 and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval in October of 2021. The POLARx FIT catheter received approval in Europe, Japan, Canada and other Asia Pacific markets in 2023. 

For more information: 

Find more HRS23 conference coverage here 


Related Content: 

Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies 

Real-world outcomes from the EU-PORIA registry of the FARAPULSE Pulsed Field Ablation (PFA) System 

Related Content

News | HRS

September 21, 2023 — Vektor Medical, developers of the only FDA-cleared technology to accurately map arrhythmias using ...

Home September 21, 2023
Feature | HRS | By Melinda Taschetta-Millane

The Heart Rhythm Society (HRS) announced the full lineup of speakers and sessions, including late-breaking clinical ...

Home May 17, 2023
News | HRS

May 2, 2023 — The Heart Rhythm Society (HRS) is making final preparations for its Annual Heart Rhythm Meeting, HRS2023 ...

Home May 02, 2023
Feature | HRS | By Lars Thording, PhD

Hospitals in the U.S. are suffering under a debilitating post-pandemic financial and operational trauma. Ascension ...

Home August 23, 2022
News | HRS

August 4, 2022 — The Heart Rhythm Society (HRS) is a professional society representing a diverse population of ...

Home August 04, 2022
News | HRS

May 17, 2022 — Heart Rhythm 2022 has come to a close, and the Heart Rhythm Society has released some stats regarding ...

Home May 17, 2022
Videos | HRS

Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of ...

Home May 22, 2020
Feature | HRS

May 20, 2020 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of them ...

Home May 20, 2020
Feature | HRS | Dave Fornell, Editor

May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm ...

Home May 15, 2019
Feature | HRS | Dave Fornell

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) ...

Home May 18, 2018
Subscribe Now